aTyr Pharma, Inc. - Common Stock ATYR 深 沪
已收盘 08-01 16:00:00 美东时间
4.70
-0.020
-0.42%
华盛通- 最 高4.755
- 今 开4.51
- 成交量 426.40万股
- 最 低 4.465
- 昨 收 4.72
- 总市值 4.18亿
- 52周最高 7.2904
- 市盈率 静 --
- 换手率 4.79%
- 52周最低 1.67
- 委 比 50.59%
- 总股本 8900.44万
- 历史最高 396.06
- 量 比 0.52
- 振 幅 6.14%
- 历史最低 1.0801
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 肠炎新药临床试验进展积极，ABVX飙涨超580%！ANEB大涨超80%
肠炎新药临床试验进展积极，ABVX飙涨超580%！公司宣布高溢价私有化计划，ANEB大涨超80%>>
07-24 19:53
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
aTyr Pharma, Inc. announced the completion of the last patient visit in its Phase 3 EFZO-FIT study of efzofitimod for pulmonary sarcoidosis. The trial enrolled 268 patients and aimed to assess efzofitimod's efficacy and safety. Topline results are expected in Q3 2025. Efzofitimod, a first-in-class immunomodulator, targets interstitial lung diseases like sarcoidosis by selectively modulating inflammation. aTyr highlights the potential to reduce st...
07-22 12:00
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
aTyr Pharma, a clinical-stage biotech company, announced its expected inclusion in the Russell 2000® and Russell 3000® Indexes following the 2025 annual reconstitution. The Russell 3000® tracks the largest 3,000 U.S. companies, with the Russell 2000® focusing on small-cap firms. aTyr is leveraging tRNA synthetase biology to develop therapies for fibrosis and inflammation, including its lead candidate efzofitimod for interstitial lung disease.
06-26 12:00
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
Wells Fargo Maintains Overweight on aTyr Pharma, Raises Price Target to $25
Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:ATYR) with a Overweight and raises the price target from $17 to $25.
06-20 20:44
aTyr Pharma Announces Findings From Interim Analysis Of Eight Patients In Ongoing Phase 2 EFZO-CONNECT Study Evaluating Efzofitimod In SSc-ILD Patients
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks.Efzofitimod was generally safe and well
06-04 20:05
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Efzofitimod has shown promising results in a Phase 2 interim analysis for treating systemic sclerosis (SSc)-related interstitial lung disease (ILD). In the analysis, three out of four patients with diffuse SSc-ILD experienced significant improvement in skin fibrosis as measured by the modified Rodnan Skin Score (mRSS). The drug was generally safe and well-tolerated, with no serious treatment-related adverse events. Additionally, preliminary data ...
06-04 12:00
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
aTyr Pharma Advances ATYR0101 To IND Candidate Stage For Pulmonary Fibrosis; Preclinical Data Demonstrate ATYR0101's Unique Anti-fibrotic Mechanism Through Interaction With LTBP-1
Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1.ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation
05-14 20:07
aTyr Pharma Q1 EPS $(0.17) Beats $(0.19) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 26.09 percent increase over losses of $(0.23) per share from the
05-08 05:25
